Genitourinary Cancer: Updates on Treatments and Their Impact on the Kidney

Paloma Orozco Scott, Priya Deshpande, Matthew Abramson

Research output: Contribution to journalReview articlepeer-review


Genitourinary cancers are diverse in their presentation, prevalence, and mortality risk. Although there have been significant advancements in medical (eg, immune checkpoint inhibitors and tyrosine kinase inhibitors) and surgical treatments of genitourinary cancers, patients are still at risk for chronic kidney disease, hypertension, and electrolyte derangements in the short and long term. In addition, pre-existing kidney disease may increase the risk of developing some genitourinary cancers. This review focuses on the kidney-related effects of treatments for renal cell carcinoma and bladder and prostate cancers.

Original languageEnglish
Article number151344
JournalSeminars in Nephrology
Issue number6
StatePublished - Nov 2022


  • Genitourinary cancer
  • bladder
  • immune checkpoint inhibitor
  • kidney
  • prostate
  • tyrosine kinase inhibitor


Dive into the research topics of 'Genitourinary Cancer: Updates on Treatments and Their Impact on the Kidney'. Together they form a unique fingerprint.

Cite this